Nucleic acid‐based antiviral and gene therapy of chronic hepatitis B infection

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Gastroenterology and Hepatology

• Publication date

  1997-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1440-1746.1997.tb00521.xPMID 9407358
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids.

  1997cited by this paper
• Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

  1996cited by this paper
• Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients

  1996cited by this paper
• Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity

  1996cited by this paper
• Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys

  1996cited by this paper
• Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.

  1995cited by this paper
• DNA vaccination against persistent viral infection

  1995cited by this paper
• Hepatitis B virus immunopathogenesis.

  1995cited by this paper
• Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

  1995cited by this paper
• Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection

  1995cited by this paper
• Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent

  1995cited by this paper
• Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.

  1995cited by this paper
• Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice.

  1995cited by this paper
• Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice

  1995cited by this paper
• DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection

  1995cited by this paper
• Characterization of hepatitis B virus core mutants that inhibit viral replication.

  1994cited by this paper
• Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells.

  1994cited by this paper
• Tissue-specific targeting of retroviral vectors through ligand-receptor interactions.

  1994cited by this paper
• Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

  1994cited by this paper
• Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

  1994cited by this paper
• Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.

  1994cited by this paper
• Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.

  1994cited by this paper
• Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.

  1994cited by this paper
• Therapy of acute and chronic viral hepatitis.

  1994cited by this paper
• Long-Term Anti-Nucleoprotein Cellular and Humoral Immunity Is Induced by Intramuscular Injection of Plasmid DNA Containing NP Gene

  1993cited by this paper
• Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance.

  1993cited by this paper
• In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

  1993cited by this paper
• Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals.

  1993cited by this paper
• Molecular virology and pathogenesis of hepatitis B

  1993cited by this paper
• Molecular virology and pathogenesis of hepatitis B.

  1993cited by this paper
• Gene inoculation generates immune responses against human immunodeficiency virus type 1.

  1993cited by this paper
• Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element

  1993cited by this paper
• Genetic Infection Induces Protective In Vivo Immune Responses

  1993cited by this paper
• Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors

  1993cited by this paper
• Ribozymes which cleave arenavirus RNAs: identification of susceptible target sites and inhibition by target site secondary structure

  1992cited by this paper
• Genetic immunization is a simple method for eliciting an immune response

  1992cited by this paper
• Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication

  1992cited by this paper
• Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template.

  1992cited by this paper
• Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1.

  1992cited by this paper
• Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.

  1992cited by this paper
• Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression

  1992cited by this paper
• Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides.

  1992cited by this paper
• Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication

  1991cited by this paper
• Primary hepatocellular carcinoma.

  1991cited by this paper
• Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better.

  1991cited by this paper
• Inhibition of hepatitis B virus by antisense oligodeoxynucleotides.

  1991cited by this paper
• Intracellular immunization

  1990cited by this paper
• Decreased Hnf-1 Gene Expression in Mice Homozygous for a 1.2-CentiMorgan Deletion on Chromosome 7

  1990cited by this paper
• Direct gene transfer into mouse muscle in vivo.

  1990cited by this paper
• Sequence requirements of the hammerhead RNA self-cleavage reaction.

  1990cited by this paper
• Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen.

  1990cited by this paper
• Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. I. T cell fine specificity.

  1990cited by this paper
• Ribozymes as potential anti-HIV-1 therapeutic agents.

  1990cited by this paper
• HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus.

  1989cited by this paper
• Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.

  1989cited by this paper
• Design of RNA enzymes distinguishing a single base mutation in RNA.

  1989cited by this paper
• The molecular biology of hepatitis B virus.

  1989cited by this paper
• Gene therapy. Intracellular immunization.

  1988cited by this paper
• Intracellular immunization

  1988cited by this paper
• Simple RNA enzymes with new and highly specific endoribonuclease activities

  1988cited by this paper
• Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.

  1988cited by this paper
• Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

  1988cited by this paper
• The chemistry of self-splicing RNA and RNA enzymes.

  1987cited by this paper
• Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent.

  1987cited by this paper
• Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

  1987cited by this paper
• Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.

  1986cited by this paper
• Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylphosphonates.

  1986cited by this paper
• Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe.

  1986cited by this paper
• Whipple's disease with unusual clinical, bacteriologic, and immunologic findings.

  1986cited by this paper
• Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

  1986cited by this paper
• Biochemical and genetic evidence for the hepatitis B virus replication strategy.

  1986cited by this paper
• The hepatitis B virus

  1985cited by this paper
• Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

  1978cited by this paper

• A recombinant adenoviral vector with a specific tropism to CD4-positive cells: a new tool for HIV-1 inhibition

  2021cites this paper
• Hepatic Tumors in Childhood

  2014cites this paper
• Antimicrobial Producing Bacteria Isolated From Petroleum-Laced Hypersaline Soil

  2013cites this paper
• Chronic hepatitis B: past, present, and future.

  2010cites this paper
• A promising alternative anti-HBV agent: the targeted ribonuclease.

  2010cites this paper
• RNAi for Treating Hepatitis B Viral Infection

  2007cites this paper
• RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant

  2005cites this paper
• Molekulare Therapie in der Gastroenterologie und Hepatologie

  2005cites this paper
• Nucleic acid-based antiviral approaches to HBV

  2003cites this paper
• Molecular Therapies for Viral Hepatitis

  2003cites this paper
• Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy.

  2003cites this paper
• Chronic Hepatitis B: Current and Future Treatment Options

  2002cites this paper
• Emerging therapies of hepatitis B and C

  2002cites this paper
• Evolving therapies for the treatment of chronic hepatitis B virus infection

  2002cites this paper
• Therapeutic strategies for hepatitis B virus-associated hepatocellular carcinoma.

  2002cites this paper
• INHIBITING HEPATITIS B VIRUS GENE EXPRESSION WITH HAMMERHEAD RIBOZYMES THAT TARGET THE HBx OPEN READING FRAME

  2002cites this paper
• Immunotherapy of hepatocellular carcinoma

  2002cites this paper
• Gen- und Immuntherapie von Lebererkrankungen

  2001cites this paper
• [Gene and immunotherapy of liver diseases].

  2001cites this paper
• Significant Interference with Hepatitis B Virus Replication by a Core-nuclease Fusion Protein*

  2001cites this paper
• Viral hepatitis. From prevention to antivirals.

  2000cites this paper
• Posttransplantation: future therapies.

  2000cites this paper
• Construction of HBV-specific ribozyme and its recombinant with HDV and their cleavage activity in vitro.

  2000cites this paper
• From Prevention to Antivirals

  2000cites this paper
• Emerging Therapies in Hepatology: Liver-Directed Gene Transfer and Hepatocyte Transplantation

  2000cites this paper
• Gene therapy for human liver diseases.

  1999cites this paper
• Antisense RNA gene therapy for studying and modulating biological processes

  1999cites this paper
• Hepatitis B virus maturation is affected by the incorporation of core proteins having a C-terminal substitution of arginine or lysine stretches.

  1999cites this paper
• New therapeutic strategies in the treatment of hepatitis B virus infection.

  1999cites this paper
• Expression of ribozymes in gene transfer systems to modulate target RNA levels.

  1998cites this paper
• The prospects of hepatic drug delivery and gene therapy.

  1998cites this paper
• New therapies for the treatment of chronic hepatitis B infection.

  1998cites this paper